Drugs / LY900020
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04047940 | Nov 2019 → Feb 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY900020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04047940 ↗ |
| Route | Oral | “LY900020 Formulation 1 administered orally” NCT04047940 ↗ |